{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T13:14:25Z","timestamp":1774271665334,"version":"3.50.1"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T00:00:00Z","timestamp":1764028800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T00:00:00Z","timestamp":1766361600000},"content-version":"vor","delay-in-days":27,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100000865","name":"Bill & Melinda Gates Foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"crossref"}]},{"name":"National Vaccine Institute (Thailand), the Government Pharmaceutical Organization"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Vaccines"],"DOI":"10.1038\/s41541-025-01321-8","type":"journal-article","created":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T13:06:36Z","timestamp":1764075996000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["One year follow up of phase 1\/2 randomized, placebo controlled trial of NDV-HXP-S vaccine in Thailand"],"prefix":"10.1038","volume":"10","author":[{"given":"Weerapong","family":"Phumratanaprapin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Viravarn","family":"Luvira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saranath","family":"Lawpoolsri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juthaporn","family":"Cowan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sant","family":"Muangnoicharoen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Supitcha","family":"Kamolratanakul","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yupa","family":"Sabmee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Piengthong","family":"Narakorn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Somchaiya","family":"Surichan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laina D.","family":"Mercer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rama","family":"Raghunandan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christina S.","family":"Polyak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ponthip","family":"Wirachwong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jorge","family":"Flores","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruce L.","family":"Innis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Punnee","family":"Pitisuttithum","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,25]]},"reference":[{"key":"1321_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2023.109968","volume":"117","author":"N Firouzabadi","year":"2023","unstructured":"Firouzabadi, N., Ghasemiyeh, P., Moradishooli, F. & Mohammadi-Samani, S. Update on the effectiveness of COVID-19 vaccines on different variants of SARS-CoV-2. Int Immunopharmacol. 117, 109968 (2023).","journal-title":"Int Immunopharmacol."},{"key":"1321_CR2","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1126\/science.abm1208","volume":"376","author":"F Obermeyer","year":"2022","unstructured":"Obermeyer, F. et al. Analysis of 6.4 million SARS-CoV-2 genomes identifies mutations associated with fitness. Science 376, 1327\u20131332 (2022).","journal-title":"Science"},{"key":"1321_CR3","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1080\/08830185.2022.2079642","volume":"42","author":"W Gong","year":"2023","unstructured":"Gong, W., Parkkila, S., Wu, X. & Aspatwar, A. SARS-CoV-2 variants and COVID-19 vaccines: Current challenges and future strategies. Int. Rev. Immunol. 42, 393\u2013414 (2023).","journal-title":"Int. Rev. Immunol."},{"key":"1321_CR4","doi-asserted-by":"publisher","first-page":"4714","DOI":"10.1080\/21645515.2021.1995283","volume":"17","author":"G Joshi","year":"2021","unstructured":"Joshi, G. et al. Exploring the COVID-19 vaccine candidates against SARS-CoV-2 and its variants: where do we stand and where do we go?. Hum. Vaccin Immunother. 17, 4714\u20134740 (2021).","journal-title":"Hum. Vaccin Immunother."},{"key":"1321_CR5","doi-asserted-by":"publisher","unstructured":"Sun, W. et al. A Newcastle disease virus (NDV) expressing a membrane-anchored spike as a cost-effective inactivated SARS-CoV-2 vaccine. Vaccines https:\/\/doi.org\/10.3390\/vaccines8040771 (2020).","DOI":"10.3390\/vaccines8040771"},{"key":"1321_CR6","doi-asserted-by":"publisher","first-page":"1875","DOI":"10.1016\/j.vaccine.2023.02.017","volume":"41","author":"E Buntinx","year":"2023","unstructured":"Buntinx, E. et al. Immunogenicity of an adjuvanted SARS-CoV-2 trimeric S-protein subunit vaccine (SCB-2019) in SARS-CoV-2-na\u00efve and exposed individuals in a phase 2\/3, double-blind, randomized study. Vaccine 41, 1875\u20131884 (2023).","journal-title":"Vaccine"},{"key":"1321_CR7","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/978-1-4939-6445-1_2","volume":"1494","author":"JD Campbell","year":"2017","unstructured":"Campbell, J. D. Development of the CpG adjuvant 1018: a case study. Methods Mol. Biol. 1494, 15\u201327 (2017).","journal-title":"Methods Mol. Biol."},{"key":"1321_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2024.126680","volume":"52","author":"EJF Peixoto de Miranda","year":"2025","unstructured":"Peixoto de Miranda, E. J. F. et al. Safety and immunogenicity of an inactivated recombinant Newcastle disease virus vaccine expressing SARS-CoV-2 spike: results of a randomized vaccine-controlled phase I ADAPTCOV trial in Brazil. Vaccine 52, 126680 (2025).","journal-title":"Vaccine"},{"key":"1321_CR9","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-023-00662-6","volume":"8","author":"S Ponce-de-Le\u00f3n","year":"2023","unstructured":"Ponce-de-Le\u00f3n, S. et al. Interim safety and immunogenicity results from an NDV-based COVID-19 vaccine phase I trial in Mexico. NPJ Vaccines 8, 67 (2023).","journal-title":"NPJ Vaccines"},{"key":"1321_CR10","doi-asserted-by":"publisher","first-page":"3621","DOI":"10.1016\/j.vaccine.2022.04.078","volume":"40","author":"A Duc Dang","year":"2022","unstructured":"Duc Dang, A. et al. Safety and immunogenicity of an egg-based inactivated Newcastle disease virus vaccine expressing SARS-CoV-2 spike: Interim results of a randomized, placebo-controlled, phase 1\/2 trial in Vietnam. Vaccine 40, 3621\u20133632 (2022).","journal-title":"Vaccine"},{"key":"1321_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2022.101323","volume":"45","author":"P Pitisuttithum","year":"2022","unstructured":"Pitisuttithum, P. et al. Safety and immunogenicity of an inactivated recombinant Newcastle disease virus vaccine expressing SARS-CoV-2 spike: Interim results of a randomised, placebo-controlled, phase 1 trial. EClinicalMedicine 45, 101323 (2022).","journal-title":"EClinicalMedicine"},{"key":"1321_CR12","doi-asserted-by":"publisher","unstructured":"Kim, D. I. et al. Immunogenicity and durability of antibody responses to homologous and heterologous vaccinations with BNT162b2 and ChAdOx1 vaccines for COVID-19. Vaccines https:\/\/doi.org\/10.3390\/vaccines10111864 (2022).","DOI":"10.3390\/vaccines10111864"},{"key":"1321_CR13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2114583","volume":"385","author":"EG Levin","year":"2021","unstructured":"Levin, E. G. et al. Waning immune humoral response to BNT162b2 Covid-19 vaccine over 6 months. N. Engl. J. Med. 385, e84 (2021).","journal-title":"N. Engl. J. Med."},{"key":"1321_CR14","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1056\/NEJMc2213907","volume":"388","author":"Q Wang","year":"2023","unstructured":"Wang, Q. et al. Antibody response to Omicron BA.4-BA.5 bivalent booster. N. Engl. J. Med. 388, 567\u2013569 (2023).","journal-title":"N. Engl. J. Med."},{"key":"1321_CR15","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1056\/NEJMc2214916","volume":"388","author":"J Zou","year":"2023","unstructured":"Zou, J. et al. Neutralization of BA.4\u2013BA.5, BA.4.6, BA.2.75.2, BQ.1.1, and XBB.1 with bivalent vaccine. N. Engl. J. Med. 388, 854\u2013857 (2023).","journal-title":"N. Engl. J. Med."},{"key":"1321_CR16","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1330549","volume":"15","author":"ND Almeida","year":"2024","unstructured":"Almeida, N. D. et al. The effect of dose-interval on antibody response to mRNA COVID-19 vaccines: a prospective cohort study. Front. Immunol. 15, 1330549 (2024).","journal-title":"Front. Immunol."},{"key":"1321_CR17","doi-asserted-by":"publisher","DOI":"10.1128\/spectrum.01538-22","volume":"10","author":"I Gonz\u00e1lez-Dom\u00ednguez","year":"2022","unstructured":"Gonz\u00e1lez-Dom\u00ednguez, I. et al. Trivalent NDV-HXP-S vaccine protects against phylogenetically distant SARS-CoV-2 variants of concern in mice. Microbiol. Spectr. 10, e0153822 (2022).","journal-title":"Microbiol. Spectr."},{"key":"1321_CR18","doi-asserted-by":"publisher","unstructured":"Barr, I. G., Rynehart, C., Whitney, P. & Druce, J. SARS-CoV-2 does not replicate in embryonated hen\u2019s eggs or in MDCK cell lines. Euro Surveill. https:\/\/doi.org\/10.2807\/1560-7917.ES.2020.25.25.2001122 (2020).","DOI":"10.2807\/1560-7917.ES.2020.25.25.2001122"},{"key":"1321_CR19","doi-asserted-by":"publisher","first-page":"3038","DOI":"10.1111\/tbed.13970","volume":"68","author":"Y Berhane","year":"2021","unstructured":"Berhane, Y., Suderman, M., Babiuk, S. & Pickering, B. Susceptibility of turkeys, chickens and chicken embryos to SARS-CoV-2. Transbound. Emerg. Dis. 68, 3038\u20133042 (2021).","journal-title":"Transbound. Emerg. Dis."},{"key":"1321_CR20","doi-asserted-by":"publisher","first-page":"3074","DOI":"10.3201\/eid2612.202989","volume":"26","author":"DL Suarez","year":"2020","unstructured":"Suarez, D. L. et al. Lack of susceptibility to SARS-CoV-2 and MERS-CoV in Poultry. Emerg. Infect. Dis. 26, 3074\u20133076 (2020).","journal-title":"Emerg. Infect. Dis."},{"key":"1321_CR21","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1126\/science.abd0826","volume":"369","author":"CL Hsieh","year":"2020","unstructured":"Hsieh, C. L. et al. Structure-based design of prefusion-stabilized SARS-CoV-2 spikes. Science 369, 1501\u20131505 (2020).","journal-title":"Science"},{"key":"1321_CR22","unstructured":"Corporation, D. T. HEPLISAV-B [Hepatitis B Vaccine (Recombinant), Adjuvanted] package insert, https:\/\/www.fda.gov\/media\/108745\/download (2020)."},{"key":"1321_CR23","unstructured":"Administration, U. S. F. a. D. Guidance for Industry: Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/toxicity-grading-scale-healthy-adult-and-adolescent-volunteers-enrolled-preventive-vaccine-clinical (2007)."},{"key":"1321_CR24","doi-asserted-by":"publisher","first-page":"e216","DOI":"10.1016\/S2666-5247(23)00324-5","volume":"5","author":"M Manak","year":"2024","unstructured":"Manak, M. et al. CEPI CLN Study Group. Standardised quantitative assays for anti-SARS-CoV-2 immune response used in vaccine clinical trials by the CEPI Centralized Laboratory Network: a qualification analysis. Lancet. Microbe. 5, e216\u2013e225 (2024).","journal-title":"Lancet. Microbe"}],"container-title":["npj Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41541-025-01321-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-025-01321-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-025-01321-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T11:30:00Z","timestamp":1766403000000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41541-025-01321-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,25]]},"references-count":24,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1321"],"URL":"https:\/\/doi.org\/10.1038\/s41541-025-01321-8","relation":{},"ISSN":["2059-0105"],"issn-type":[{"value":"2059-0105","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,25]]},"assertion":[{"value":"13 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"261"}}